High pretherapeutic thymidylate synthetase and MRP‐1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients
Authors:
- 29 June 2010
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 102 (5) , 503-508
Abstract
Background: The aim of this study was to determine whether pretherapeutic protein expression levels of the excision repair cross‐complementing (ERCC1) enzyme, thymidylate synthetase (TS), multidrug‐resistance protein 1 (MRP‐1) and P‐glycoprotein (P‐gp) are associated with tumour response to cisplatin and fluorouracil (5‐FU)‐based neoadjuvant chemotherapy in oesophageal adenocarcinomasMethods: The expression levels of ERCC1, TS, MDR‐1 and P‐gp were determined immunohistochemically in pretherapeutic tumour biopsies from 40 oesophageal adenocarcinoma patients and were correlated with histopathological tumour regression and with patient survival. Protein expression was compared to mRNA data, which was previously published for ERCC1, TS and MRP‐1 and newly determined for the purpose of this study for MDR‐1/P‐gp.Results: High‐TS and ‐MRP‐1 protein expression was correlated with tumour non‐response to chemotherapy (P = 0.001 and P = 0.036, respectively). For ERCC‐1 and P‐gp, no association between pretherapeutic protein expression and response was found. There was no correlation between mRNA levels and protein expression for all investigated markers. Survival analysis revealed a trend towards increased survival for low‐ERCC‐1 expression (P = 0.079).Conclusions: The pattern of pretherapeutic expression of TS and MRP‐1 is related to chemotherapy response in oesophageal adenocarcinoma patients. Immunohistochemical assessment of these markers may be helpful for response prediction. J. Surg. Oncol. 2010;102:503–508.Keywords
This publication has 30 references indexed in Scilit:
- Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literatureLung Cancer, 2009
- Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy ResponseClinical Cancer Research, 2008
- Predictors of response and survival for neoadjuvant treated patients with esophageal adenocarcinomaDiseases of the Esophagus, 2008
- Histopathologic Examination and Reporting of Esophageal Carcinomas Following Preoperative Neoadjuvant TherapyAmerican Journal of Clinical Pathology, 2008
- Comparison of Pretherapeutic and Posttherapeutic Expression Levels of Chemotherapy-Associated Genes in Adenocarcinomas of the Esophagus Treated by 5-Fluorouracil– and Cisplatin-Based Neoadjuvant ChemotherapyAmerican Journal of Clinical Pathology, 2007
- American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal AdenocarcinomaJournal of Clinical Oncology, 2007
- Biomarkers of Response to Preoperative Chemoradiation in Esophageal CancersSeminars in Oncology, 2006
- Pretherapy nuclear factor-κB status, chemoradiation resistance, and metastatic progression in esophageal carcinomaMolecular Cancer Therapeutics, 2006
- Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer PatientsClinical Cancer Research, 2005
- Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancerJournal of the American College of Surgeons, 2005